Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Equity Average (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Equity Average for 6 consecutive years, with $93.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average fell 40.86% year-over-year to $93.5 million, compared with a TTM value of $93.5 million through Sep 2025, down 40.86%, and an annual FY2024 reading of $158.5 million, down 26.31% over the prior year.
  • Equity Average was $93.5 million for Q3 2025 at Barinthus Biotherapeutics, down from $109.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $254.0 million in Q2 2022 and bottomed at -$44.9 million in Q1 2021.
  • Average Equity Average over 5 years is $178.0 million, with a median of $191.3 million recorded in 2023.
  • The sharpest move saw Equity Average soared 948.0% in 2021, then crashed 40.86% in 2025.
  • Year by year, Equity Average stood at $247.5 million in 2021, then fell by 1.55% to $243.7 million in 2022, then decreased by 21.49% to $191.3 million in 2023, then dropped by 24.34% to $144.7 million in 2024, then tumbled by 35.39% to $93.5 million in 2025.
  • Business Quant data shows Equity Average for BRNS at $93.5 million in Q3 2025, $109.0 million in Q2 2025, and $122.8 million in Q1 2025.